Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fesoterodine vs Tolterodine ER in Overactive Bladder
NCT00611026Phase 3Completed
- Sponsor
- Pfizer
- Start
- Feb 2008
- Primary completion
- Oct 2009
- Modality
- Small Molecules
- Countries
- 25
01
Overview
Phase 3, randomised, double-blind trial of fesoterodine in overactive bladder (OAB) (3 arms), sponsored by Pfizer. Primary endpoint: Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at 12 weeks. Started Feb 2008; status: completed.
02
Drugs
fesoterodine
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT00611026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00611026.